Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.

Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL; CRESCENDO Investigators.

Lancet. 2010 Aug 14;376(9740):517-23. doi: 10.1016/S0140-6736(10)60935-X.

PMID:
20709233
2.

The effects of cyclooxygenase-2 expression in prostate cancer cells: modulation of response to cytotoxic agents.

Mehar A, Macanas-Pirard P, Mizokami A, Takahashi Y, Kass GE, Coley HM.

J Pharmacol Exp Ther. 2008 Mar;324(3):1181-7. Epub 2007 Dec 18.

3.

Spironolactone responsive familial hypertension. A potentially high prevalence of mineralocorticoid disease in Oman.

Woodhouse NJ, Elshafie OT, Mehar A, Johnston WJ, Al-Kaabi JM.

Saudi Med J. 2003 Feb;24(2):229-31. No abstract available.

PMID:
12682699
4.

Spatial and temporal regulation of the pesticide dieldrin within industrial catchments

Mehar AA, Wright J, Leeks GJ, Wass P, Osborn D.

Sci Total Environ. 2000 May 5;251-252:255-63.

PMID:
10847166
5.

Isolation and fusion studies on protoplasts from pollen tetrads.

Deka PC, Mehar AK, Pathak NN, Sen SK.

Experientia. 1977 Feb 15;33(2):182-4.

PMID:
321241
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk